Shanghai-based biotechnology company Harbour BioMed, backed by Chinese investment firms Advantech Capital and Legend Capital, has acquired Netherlands-headquartered firm Harbour Antibodies BV to create a global oncology-focused biotechnology company.
Harbour BioMed used a combination of cash and equity to acquire the Cambridge, Massachusetts-based firm, says an announcement. No financial details were announced.
The acquisition was financed by Harbour BioMed's investors, Advantech Capital and Legend Capital, two China-focused investors with a particular emphasis on life sciences.
Harbour Antibodies' existing shareholders, ...
This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network